International Journal of Hematology

, Volume 77, Issue 5, pp 482–489

Prognostic Significance of CD7+CD56+ Phenotype and Chromosome 5 Abnormalities for Acute Myeloid Leukemia M0

  • Ritsuro Suzuki
  • Makoto Murata
  • Masahiro Kami
  • Shigeki Ohtake
  • Norio Asou
  • Yoshihisa Kodera
  • Masao Tomonaga
  • Yasufumi Masaki
  • Shuya Kusumoto
  • Jin Takeuchi
  • Shin Matsuda
  • Hisamaru Hirai
  • Seiichi Yorimitsu
  • Nobuyuki Hamajima
  • Masao Seto
  • Masanori Shimoyama
  • Ryuzo Ohno
  • Yasuo Morishima
  • Shigeo Nakamura
Article

DOI: 10.1007/BF02986617

Cite this article as:
Suzuki, R., Murata, M., Kami, M. et al. Int J Hematol (2003) 77: 482. doi:10.1007/BF02986617

Abstract

Myeloid/natural killer (NK) cell precursor acute leukemia is an entity of acute leukemia characterized by poor prognosis and a CD7+CD56+ myeloid antigen+ phenotype without light-microscopic myeloperoxidase reactivity. This disease shares several clinical characteristics with acute myeloid leukemia (AML) M0. To clarify the relationship between these 2 leukemias, we analyzed 105 cases of AML M0. Among them, 17 were CD7+ and CD56+, 77 were negative for either antigen, and 11 could not be determined. CD7+CD56+ AML M0 showed onset at significantly lower patient age (median 46 versus 63 years,P =.004). The disease localization and the hematological manifestations were significantly different: CD7+CD56+ AML showed more frequent extramedullary involvement, fewer circulating leukemic blasts, less anemia, and less thrombocytopenia than did AML M0. The cytogenetic aberrations were also unique, because no 5q abnormalities were found in CD7+CD56+ M0. The prognosis of CD7+CD56+ M0 was poor in patients younger than 46 years(P =.03). Multivariate analysis showed that the CD7+CD56+ phenotype was a significant prognostic factor for AML M0, as well as age, circulating blast percentage, and chromosome 5 abnormalities. These findings suggest that AML M0 consists of heterogeneous subgroups to be managed separately, and CD7+CD56+ M0 constitutes a distinct subtype of AMLM0.

Key words

AML M0Myeloid/NK cell precursor acute leukemiaCD7CD56Prognosis

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Ritsuro Suzuki
    • 1
    • 2
  • Makoto Murata
    • 6
  • Masahiro Kami
    • 7
  • Shigeki Ohtake
    • 8
  • Norio Asou
    • 9
  • Yoshihisa Kodera
    • 10
  • Masao Tomonaga
    • 11
  • Yasufumi Masaki
    • 12
  • Shuya Kusumoto
    • 13
  • Jin Takeuchi
    • 14
  • Shin Matsuda
    • 15
  • Hisamaru Hirai
    • 16
  • Seiichi Yorimitsu
    • 17
  • Nobuyuki Hamajima
    • 3
  • Masao Seto
    • 1
  • Masanori Shimoyama
    • 18
  • Ryuzo Ohno
    • 5
  • Yasuo Morishima
    • 2
  • Shigeo Nakamura
    • 4
  1. 1.Division of Molecular MedicineNagoya
  2. 2.Department of Hematology and ChemotherapyNagoya
  3. 3.Division of Epidemiology and PreventionNagoya
  4. 4.Department of Pathology and Molecular DiagnosisNagoya
  5. 5.Aichi Cancer CenterNagoya
  6. 6.Department of Internal MedicineNagoya University School of MedicineNagoya
  7. 7.Department of HematologyToranomon HospitalTokyo
  8. 8.Third Department of Internal MedicineKanazawa University School of MedicineKanazawa
  9. 9.Second Department of Internal MedicineKumamoto University School of MedicineKumamoto
  10. 10.Department of Internal MedicineJapanese Red Cross Nagoya First HospitalNagoya
  11. 11.Department of HematologyNagasaki University School of MedicineNagasaki
  12. 12.Department of Internal MedicineKanazawa Medical UniversityIshikawa
  13. 13.First Department of Internal MedicineSaitama Medical SchoolSaitama
  14. 14.First Department of Internal MedicineNihon University School of MedicineTokyo
  15. 15.Center for Hematopoietic DisordersOhta Nishinouchi HospitalKoriyama
  16. 16.Department of Hematology and OncologyFaculty of Medicine, University of TokyoTokyo
  17. 17.Department of Internal MedicineKochi Central HospitalKochi
  18. 18.National Nagoya HospitalNagoyaJapan